We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Spruce Biosciences Inc | NASDAQ:SPRB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0038 | 0.56% | 0.6778 | 0.6777 | 0.6778 | 0.6823 | 0.66 | 0.67 | 401,531 | 00:46:49 |
Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH)
The company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a poster presentation
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
In addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CAH, as an illustration of outcomes of current pediatric CAH disease management, was accepted for poster presentation at the PES conference.
PES 2024 Poster Presentation Details:
Title: Baseline Characteristics of CAHptain: A Phase 2 Dose-finding Study of Tildacerfont in Children with Classic Congenital Adrenal Hyperplasia Abstract Number: 6899 Poster Session: 2 Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT Presenter: Mimi S. Kim, M.D., Co-Director, Congenital Adrenal Hyperplasia Comprehensive Care Clinic, Children’s Hospital Los Angeles
Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia Abstract Number: 6898 Poster Session: 2 Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence
The poster presentations will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430222156/en/
Media Contact Katie Beach Oltsik Inizio Evoke Comms (937) 232-4889 Katherine.Beach@inizioevoke.com media@sprucebio.com Investors Samir Gharib President and CFO Spruce Biosciences, Inc. investors@sprucebio.com
1 Year Spruce Biosciences Chart |
1 Month Spruce Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions